l 00 years, there has been an epidemic of vascular disease (American Heart Association, 2003) . Data from the Framingham study (Castelli, 1984 (Castelli, , 1992 reported that by age 60, one in five men have one fonn of coronary heart disease (CHO), 1 in 17 women have some form of CHO, and l in 15 men and women would eventually have a stroke. In 1999, statistics revealed that vascular disease was responsible for 529,659 deaths in the United States. Approximately every 29 seconds, an American will experience a coronary event and approximately every minute someone will die from a coronary event (American Heart Association, 2003) . Risk factors for vascular disease, when not recognized or optimally treated, lead to heart attack, peripheral vascular disease, or stroke (NCEP, 2001) .
Progress has been slow in stamping out this pandemic of cardiovascular disease. Each year, more than 1 million Americans have a new or recurrent myocardial infarction (MI), and approximately 40% of them die. The American Heart Association (2003) estimated that in 2001 the total yearly cost of treating CHO in the United States was $111.8 billion, an increase of 16% from 1998. Indirect costs caused by lost productivity were estimated at $53.6 billion, of which $8.4 billion was related to morbidity and $45.2 billion was related to mortality. Other estimated costs include hospital and nursing home costs at $41.8 billion, and physician, nurse, and other professional services costs of $8.6 billion.
Since the inception of the first NCEP guidelines in 1988, the focus of prevention has been on reduction of LDL cholesterol, treatment of hypertension and diabetes, and lifestyle management (Grundy, 2001; NCEP, 2001) . Family history has been reinforced as a strong risk factor, especially when it co-exists with other traditional risk factors (Rader, 1998) . Data from clinical studies have established a strong correlation between LDL and risk of CAD (Grundy 2001; Lenfant, 1996; Levine, 1995) . However, results of prospective "statin" trials reveal reduction of LDL only reduced the incidence of new, or progression of current dis· ease by 30% to 40% (Brown, 200 I; Gould, 1995) .
Compelled by new insights into the pathobiology of cardiovascular disease, coupled with the current environmental milieu, investigators have sought to identify independent markers with which to more fully assess cardiovascular risk. Several "novel" risk factors for atherosclerosis including lipoprotein (a) [Lp(a)] (Rader, 2000a; Superko 1995 Superko , 1996 , apolipoprotein B (apo B), (Austin, 2000; Rader, 2000a) , fibrinogen (Levenson, 1995) , C-reactive protein (CRP) (Ridker, 2001 ) , and homocysteine (Superko, 1995; Welch, 1998) have emerged, independent of cholesterol levels. Because consistent findings among researchers reinforce the complex multifactorial etiology of atherosclerosis, a consensus is emerging that use of these factors can more appropriately assess those at risk, thereby reducing vascular events, both primary and secondary. Strong evidence exists that aggressive treatment can reduce or even halt the progression of known disease.
A distinct relationship has been identified between dyslipidemia and CHD. Prior to the new guidelines presented in May 2001, approximately 26 million Americans were candidates for lipid lowering drug therapy for both primary and secondary prevention. However, only approximately 5.3 million were receiving it (Jacobson, 2000; Pearson, 2000; Third National Health and Nutrition Examination Survey [NHANES III], 2000) . The new guidelines have identified individuals with other forms of atherosclerotic disease (e.g., peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid disease) and individuals with known diabetes mellitus. In addition, based on the Framingham scoring, individuals with a l 0 year risk for CHD greater than 20% need to have their LDL cholesterol at less than 100 mg/dL. Thus, many more clients are candidates for therapy (NCEP, 2001; Olson, 2001; Pearson, 2000) .
A number of hypotheses exist related to why clients are not treated to meet the goals set by the guidelines for cholesterol, blood pressure, or glucose levels, although the reasons are not well understood. Some believe that survival after an MI is unaffected by intervention. There is also a feeling that the problem has been cured by angioplasty or a coronary artery bypass graft. Based on an insufficient knowledge base, the health care provider may not feel comfortable providing counseling for clients about lipid disorders. drug therapy, and nutrition. Clients may be reluctant to initiate lifestyle changes. Frequently, there is poor compliance with long tem1 drug therapy. The client may be concerned about the expense of the medication and any other health risks associated with lipid lowering medications. It requires a change in paradigms of health care providers, clients, and insurance carriers to correct this problem.
Not only have the identification and treatment modalities for vascular disease improved over the years, but criteria have improved as well. In the 1950s, the diagnosis of an MI was based on symptoms and the presence of clinical features including fever, elevated white blood count, and elevated sedimentation rate. Ancillary to physical findings and presenting symptoms, the diagnosis of cardiovascular disease in the year 2000 includes assessment of inflammatory processes, properties affecting thrombus formation, endothelial function, and lipid evaluation (Libby, 2001 ) .
Attention is currently focused on atherosclerotic plaques as key pathology in the development of an Ml. The two types of plaque include stable and unstable. Unstable plaque is vulnerable to rupture, resulting in an inflammatory response, damage to the endothelium, and the development of foam cells (Libby, 2001) . Unstable plaques produce approximately 68% of all Mis, and are representative of obstructions greater than 50%. Obstructions between 50% and 70% are believed to be responsible for approximately 18% of all Mis, and coronary obstructions greater than 70% are thought to be responsible for 14% (Davidson, 2002; Levine, 1995; Libby, 2001; McKenny, 2001) .
GOALS OF CARE
The goals of care involve three maxims: identification of the risk; treatment of individuals, not diseases; and retarding progression of existing disease. In a 1999 study of CHD risk factor clustering, six risk factors were considered: • Increased triglycerides. • Increased total cholesterol. • Increased systolic blood pressure. • Increased body mass index. • Increased serum glucose.
• Decreased HDL cholesterol.
The outcome of the study was that clusters of three or more risk factors were associated with twice the risk than those predicted by chance. Clusters of three or more risk factors resulted in an increase of 2.4 times the CHD risk in men and 5.9 times the risk in women (Wilson, 1999) .
Initial assessment for vascular disease includes a history of cardiovascular disease or cardiac equivalents, such as symptomatic carotid disease, abdominal aortic aneurysm, or diabetes mellitus, along with traditional risk factors of hypertension, cigarette smoking, low HDL, and family history of premature CAD. Additional risk factors include stress levels, obesity, lack of exercise; and known secondary causes such as medications and physiological conditions (e.g., thyroid disease, nephritic syndrome, obstructive liver disease). Medical and surgical histories are also essential components. If the client's primary lipid problem is an elevated triglyceride level, a history of recurrent abdominal pain or pancreatitis is important because a client with a fasting triglyceride level of greater than 1,000 mg/dL is at high risk for the development of pancreatitis (Rader, 2000a) .
DIAGNOSIS OF HYPERLIPIOEMIA
There are a variety of lipid disorders. Six of the most common disorders seen in clinical practice include:
The diagnosis of each relies on a combination of factors (see Table) .
High Density Llpoprotslns
Optimal levels of HDL are greater than 40 mg/dL. Elevated levels of HDL are associated with reduced inci- dence of CAD. Assmann (1996) reported that HDL levels of less than 35 mg/dL correlated significantly with higher incidence of CAD, and levels greater than 55 mg/dL were associated with decreased risk. Low levels of HDL with triglyceride levels of greater than 200 mg/dL, have been found to increase cardiovascular risk by five fold. This risk persists through age 80. High density lipoprotein is associated with reduction of atherogenic changes in a number of ways. It reverses cholesterol transport, assisting with the return of LDL to the liver for excretion in bile. High density lipoprotein also has other properties that may be cardioprotective, such as interference with LDL aggregation (i.e., clumping), oxidation of LDL, endothelium repair, enhanced fibrinolysis (i.e., breaking down clots), normal coronary vaso reactivity, reduced erythrocyte aggregation, lower blood viscosity, and decreased platelet aggregation (Rader, 2000a (Rader, , 2002 .
Triglycerides
A number of atherogenic changes are associated with high triglyceride levels. These include increased very low density lipoprotein (VLDL) remnants; low HDL; small, dense LDL particles; increased chylomicron remnants; and coagulation changes (Miller, 1998; Szapary, 2001) . In addition, an elevated triglyceride level of more than l ,000 mg/dL can impair oxygen release from the red blood cells resulting in myocardial ischemia and chest pain. Levels of triglycerides greater than l,000 mg/dL are also associated with increased risk for pancreatitis (Rader, 2000a) . Castelli (1992) found that triglyceride levels greater than 250 mg/dL in women substantially increased CHO risk.
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Low Density Llpoprotelns
The guidelines for LDL cholesterol level goals developed by the NCEP (2001) are as follows: • Less than 160 mg/dL with less than or one traditional risk factor for CAD. • Less than 130 mg/dL with two or more traditional risk factors. • Less than I 00 mg/dL with known coronary, symptomatic carotid, or peripheral artery disease, individuals with abdominal aortic aneurysms, and diabetes mellitus.
Studies of LDL cholesterol levels often include identification of LDL particle sizes. The smaller and more dense the LDL particle is, the higher the risk for CAD. Superko ( 1995 Superko ( , 1996 reported the incidence of small, dense LDL as 50% in men, 20% in pre-menopausal women with CAD, and 50% in post-menopausal women. Small, dense LDL increases the risk for CAD threefold. Because LDL particle sizes do effect CAD, patterns have been identified associated with particle sizes. Pattern A clients have larger, fluffier LDL particles. These clients are generally not insulin resistant, have normal glucose and insulin levels, have normal range HDL levels, and do not have elevated blood pressure. Conversely, clients with smaller, more dense particles (Pattern B) generally have higher glucose levels (greater than 110 mg/dL), higher insulin levels, higher triglyceride levels, lower HDL levels, and higher blood pressure. They are often insulin resistant and are frequently overweight, consistent with metabolic syndrome (Austin, 2000) . The small, dense particles in Pattern B can increase the risk for CAD by 300%.
Changes in this atherogenic pattern can be achieved with diet, exercise, weight control, and, when appropri-ate, lipid lowering medications. The NCEP Adult Treatment Plan (ATP) III guidelines emphasize identification of individuals who fit these criteria and urge treatment through therapeutic lifestyle changes, including intense weight management, increased physical activity, and treatment of nonlipid risk factors of hypertension and smoking. Using the Framingham Risk Assessment in clients with metabolic syndrome frequently results in stratification for LDL at less than 100 mg/dL, or treatment as a cardiac equivalent.
Clinical identification of the metabolic syndrome includes any three or more of the following factors (NCEP, 2001; Sz.apary, 2001 ):
• Waist circumference greater than 40 inches for men and greater than 35 inches for women. • Triglycerides greater than 150 mg/dL. • High density lipoprotein cholesterol less than 40 mg/dL for men and less than 50 mg/dL for women. • Blood pressure greater than or equal to 130/85 mmHg. • Fasting glucose greater than or equal to 110 mg/dL.
Othsr TBSl/ng
For the individual with two or more traditional risk factors, especially if one includes family history, other testing may be prudent to fully evaluate risk. As previously stated, investigators have identified five substances in the blood that provide valuable data for assessment of future vascular events. These substances are referred to as independent risk factors for vascular disease and are tested separately from traditional risk factors.
These tests include Lp(a), apo B, homocysteine, CRP, and fibrinogen. If one or more of these substances is elevated, the client is at higher risk for developing vascular disease. This is true even if LDL cholesterol is close to target level (Rader 2000a; Superko 1995 Superko , 1996 .
Lipopmtein (a). Lipoprotein (a) is an LDL variant, largely a genetic trait, which is a strong marker for vascular disease (Rader, 1992) . It has been termed the "enigmatic particle" because its pathogenic mechanism is unclear and its concentration and atherogenicity vary among ethnic groups. Lipoprotein (a) has a unique design. Ordinarily, LDL is a ball of cholesterol wrapped by a strand of protein. As LDL travels through an artery, this protein can latch onto plaque and deliver the cholesterol cargo. Analysis of Lp(a) reveals an extra strand of protein shaped like a natural clot buster in the blood. Because plaque is known to contain blood clots, scientists suspect this lookalike protein actually tricks blockages into soaking up more cholesterol. It is suggested that elevated levels of Lp(a) may inhibit activation of plasminogen to plasmin, thickening the blood and stiffening the walls of arteries. Lipoprotein (a) should be less than 20 mg/dL or can be twice that high in African Americans.
Individuals with elevated Lp(a) have a 70% greater risk of MI during a 10 year period, than individuals with lower levels. An Lp(a) of 30 mg/dL is equivalent to triglycerides greater than 240 mg/dL, or HDL Jess than 35 mg/dL (Superko, 1996) . Increased levels are associated with early MI, carotid atherosclerosis, and percutaneous transluminal coronary angioplasty restenosis (i.e., closing of the angio-524 plasty). Lipoprotein (a) increases prothrombic activities, increases the oxidative susceptibility of LDL molecules, and significantly increases risk for obstructive vascular disease in the presence of high LDL and low HDL. The concentration of Lp(a) and its ability to cause increased cardiovascular risk varies among ethnic groups. Ethnic differences in Lp(a) levels are not well understood.
Fluctuations on Lp(a) levels are seen in women with diabetes mellitus, who take estrogen, who are pregnant, and who are post-menopausal. That Lp(a) levels increase by approximately 20% at menopause could correlate with the increased risk of heart disease at that time. Other causes of increased Lp(a) include hypothyroidism, kidney disease, and dietary consumption of trans-fatty acids, found in margarine, cookies, crackers, and restaurant fried foods (Rader, 1992; Szapary, 2002) .
Treatment to lower Lp(a) is limited. Diet or other lifestyle changes do not appear to influence Lp(a). It remains uncertain whether lowering Lp(a) alone is beneficial. However, the identification of an elevated Lp(a) can influence the treatment plan for the reduction of LDL cholesterol, specifically with the addition of certain medications. Because Lp(a) is believed to be an inherited genotype 95% of the time and predominately an inherited risk factor, health care providers should suggest that the individual's family members also be tested for elevated LDL and Lp(a) when elevated Lp(a) levels are identified.
Clients who take niacin preparations, and postmenopausal women taking estrogen replacement therapy have been able to decrease their levels of Lp(a). Niacin therapy in men and hormone replacement therapy (HRT) in women are reasonable choices for Lp(a) reduction because they are the only medications currently available for that purpose. However, prescribing HRT for this sole purpose is no longer considered appropriate, given the recent research and specifically, the position of investigators in the Writing Group for the Women's Health Initiative (2002) that HRT should not be used for the purpose of preventing CAD. Niacin is beneficial in reducing total cholesterol and in increasing HDL cholesterol levels.
Apolipoprotein B. Apolipoprotein B is a lipoprotein (i.e., a combination of a lipid or fat, and a protein) found in the blood. The proteins in lipoproteins are called apolipoproteins. Abnormalities in apo B are thought to be inherited. This trait occurs in 1 of approximately 700 individuals throughout the world, regardless of race. A level of apo B less than 130mg/dL is considered normal (Rader, 1998 (Rader, , 2000a ).
An increased number of apo B particles can indicate an increased risk of CAD from elevated levels of the small, dense particles of LDL in the blood. Individuals who have a defect in the apo B gene clear LDL from the blood more slowly. This condition results in higher LDL levels and leads to increased plaque buildup (Rader, 2000a) .
Clinical studies have shown that participants with elevated levels of apo B also had an increased risk of developing cardiovascular disease, even if their lipid levels were relatively normal. Researchers (Rader, 2000a; Superko, 1996) conducting large clinical trials have consistently reported:
• Participants with increased apo B levels also have increased levels of small, dense LDL particles, and a threefold to fivefold increase in risk of developing cardiovascular disease. • Low density lipoprotein was cleared more slowly from the blood of individuals with a defective apo B gene, resulting in high LDL levels.
• Elevated levels of dense LDL, consistent with elevated levels of apo 8, have been found in 40% to 50% of men with known cardiovascular disease. An apo 8 level greater than 130 mg/dL is considered elevated. To date, women have not been studied as a group in terms of elevated apo 8. Many cardiovascular specialists and researchers believe that current data can be extrapolated to women as well.
• Elevated levels of apo 8 are common in individuals with diabetes, low HDL levels, and combined hyperlipidemia (i.e., total cholesterol greater than 200 mg/dL plus triglycerides greater than 150 mg/dL).
. As with other independent risk factors for card10vascular disease, identification of high levels of apo 8 is useful in targeting LDL levels and selecting appropriate medication. Treatment for elevated levels of apo 8 is similar to treatment for combined hypercholesterolemia. The treatment program includes losing weight, increasing exercise, and taking medications such as statins, niacin, or fibrates.
Homocysteine. Homocysteine is an amino acid which is an intermediate product of protein metabolism. Studies have demonstrated a strong relationship between cardiovascular disease and elevation of homocysteine levels. This highly reactive metabolite of methionine, when elevated, causes damage to the vessel walls. A homocysteine level greater than 1 Omg/dL is considered elevated. This may vary from one laboratory to another with ranges from lOmg/dL to 14mg/dL. The gene that carries homocysteine is passed down from one generation to the next, indicating a strong inherited influence (Stoney, 2000a) .
Increased levels of homocysteine are also associated with aging, menopause, chronic renal failure, organ transplantation, and medications (e.g., niacin, methotrexate). Additionally, there may also be a decrease in the productivity or action of key enzymes in the metabolism of homocysteine. Known as a silent condition, elevated homocysteine has no signs or symptoms, but it does cause damage to the endothelium.
Clients with elevated homocysteine levels have more than three times the risk of developing cardiovascular disease than those with normal levels (Kulla, 2000; Superko, 1995) . Elevated levels are also found in individuals with premature CAD. Homocysteine levels rise during menopause, and are lower during pregnancy and when estrogen replacement therapy is used. These findings support the theory that a decrease in female sex hormones is, in part responsible, for gender related increases in homocysteine.
In general, men have decreased levels of folic acid, 86, and 812. For that reason, they can also have higher levels of homocysteine than women. Smokers, both men and women, have homocysteine levels that are approximately 23% higher than the general population. Although the exact mechanism that causes this is unknown, it is known that smokers have lower levels of vitamins 86 and 812 in their bodies. The increase in homocysteine has been shown to be reversed when clients stop smoking (Kulla, 2000) . Some of the problems resulting from increased homocysteine levels are: • Damage to the cell wall.
• Changes in clotting factors such as increased levels of fibrinogen. The degree of changes in clotting mechanism may be related to the degree of homocysteine elevation. • Oxidation of LDL particles, making LDL more likely to cause damage. Research indicates when LDL particles come in contact with oxygen, the LDL particle is more likely to cause heart disease. The specific mechanism is unknown (Eikelboom, 1999; Rader, 2000a ). • Homocysteine levels increase when an individual expresses hostility and anger, or is under stress (Stoney, 2000b) . This finding may explain the link between these emotional states and increased risk for CAD. An increased homocysteine level of 5 mg/dL is comparable to a 20 mg/dL increase in total cholesterol, and has been associated with an increased risk of CAD.
Reduction of homocysteine levels has been associated with an estimated 50,000 American lives being saved (8oushey, 1995) . Nonetheless, widespread screening for elevated levels of homocysteine in the general population is not advocated.
Certain groups of people may be at higher risk for elevated homocysteine levels than others, and may benefit from screening. One group includes those who have developed atherosclerotic disease earlier than would be expected for their age, especially if they have no signs of traditional risk factors. Although this is useful in determining risk, those with known cardiovascular disease also benefit from the testing because it is important to protect the lining of the blood vessels to prevent progression of existing disease (Vasan, 2003) .
Although evidence links elevated homocysteine with cardiovascular disease, no clinical trial results exist indicating that treatment with folic acid, and in some cases other B vitamins, reduces the incidence of cardiovascular disease. However, this treatment has been shown to be effective in clinical practice by cardiologists and primary care providers. Acceptable levels of homocysteine are variable, but less than 10 mg/dL is the goal at the University of Pennsylvania practice based on its positive association to CAD related to the potential for damage to the endothelium (Vasan, 2003) . When elevated levels are identified, 1 mg daily of folic acid is prescribed. Generally accepted treatment ranges from 1 mg to 5 mg daily.
C-reactive protein. Evidence is mounting that CAD is an inflammatory process as well as a disease of dyslipidemia. This is based on histologic examination of pathologic specimens obtained from CAD clients. C-reactive protein is an acute phase reactant believed to contribute to the atherogenic process. Ridker (200 l, 2002 ) studied participants in both the Physicians Health Study Research Group (1989) and CARE Trial (Sacks, 1996) , finding a positive correlation with participants with high levels of CRP and future CAD. Evidence indicates that elevated CRP and LDL cholesterol are strong predictors of future CAD events-the risk is compounded when both of these factors exist simultaneously (Ridker, 2002) . Specifics related to the CRP marker include (Cohn, 2003; Kennon, 2001; Ridker, 2002 ): • C-reactive protein is currently measured with a specific hs-CRP assay-a high sensitivity test that has been designed lo detect smaller amount of CRP than the standard CRP testing of the past. The newer test is specific for use in identifying cardiovascular risk.
• Studies demonstrate a threefold to fourfold increased risk associated with the highest quartile compared with the lowest levels.
• The CRP levels can be elevated in clients who have a cold, infection, arthritis, or other inflammatory processes. For this reason, serial testing is recommended before treatment is instituted based on this independent risk factor. • The hs-CRP has been decreased with exercise, statin therapy, extended-release niacin (Niaspan), and aspirin. • Treatment of isolated elevated CRP levels remains a question for some clinicians because no data exist to indicate that this would reduce CAD risk when found apart from other risk factors.
Fibrinogen. Fibrinogen is a protein that is part of a very complex system designed to control blood clotting and viscosity. Studies consistently show that when fibrinogen levels are evaluated along with lipid levels, the risk of heart disease significantly increases. Levels of fibrinogen appear to be, in part, genetically determined. However, levels are not consistent within groups of men or women or within ethnic groups. When fibrinogen levels are too high (i.e., greater than 300 mg/dL), there is a tendency for blood to clot or coagulate, and for the body to interrupt its natural mechanism to control blood viscosity. Increased coagulation and viscosity have been found to contribute to the development of cardiovascular disease by encouraging clot formation within the blood vessels (Ma, 1999) . Elevated fibrinogen levels have been noted in individuals with angina who later experienced an MI (Levenson, 1995; Rader, 2000a; Superko, 1996) .
Studies of fibrinogen demonstrate that: • Men have higher levels of fibrinogen than women. • Black individuals have higher levels than White individuals. • Individuals with both elevated fibrinogen and elevated LDL cholesterol have an increased risk for development of cardiovascular disease. This risk is greater than if either level were elevated individually.
• Increased levels of fibrinogen may result from increased age, chronic infection, stress, smoking, elevated insulin levels, increased body fat, sedentary lifestyle, oral contraceptives, and menopause. • Individuals with elevated fibrinogen levels experience increased growth of abnormal masses of cholesterol, clumping of platelets, and increased blood viscosity-all of these factors contribute to CAD (Miller, 1998) .
Treatment for elevated fibrinogen includes smoking cessation, weight loss, and increased physical activity. No medications except aspirin (Ma, 1999) are routinely used to reduce ftbrinogen levels, although several are under investigation including fibrates, antiplatelets, anticoagulants, fish oils, and estrogen replacement therapy.
Othsr Risk Factors
Current data suggest that individuals with cholesterol levels within normal range could still be at risk for developing cardiovascular disease. Testing for independent risk factors in addition to traditional risk factors can be performed to enhance risk assessment, especially if a family history of CAD is identified.
Initial assessment of the individual includes a health history and thorough physical examination with vital signs, heart sounds for abnormalities, pulses, and abdominal examination (e.g., for bruit). Evaluation of outward manifestations of hyperlipidemia include eye examination for arcus cornea, eyelids for xanthelasma (i.e., yellowish deposits of cholesterol), palms for palmar xanthomas, knuckles and Achilles tendons for tendon xanthomas, and elbows and knees for cutaneous tuberoeruptive xanthomas (McKenny, 2001) . Palpation of the thyroid is also essential. If laboratory results indicate primarily a triglyceride problem, health care providers must also include a search of the eyes for lipemia retinalis and the back and buttocks for eruptive xanthomas. These findings represent a buildup of cholesterol in the body because it is not able to dispose of the cholesterol appropriately. Xanthomas are clusters of cholesterol, the characteristics of the xanthoma are related to the particular lipid abnormality (Rader, 2000a (Rader, , 2002 .
After risk factors (both traditional and independent as appropriate), the physical examination, and other data have been evaluated, attention is drawn toward the treatment plan. If all forms of CAD were eliminated, total life expectancy would be increased by 9.8 years; if all forms of cancer were eliminated, the total increase in life expectancy would be 3 years (Kong, 2000) . These data compel health care providers to assess and aggressively treat all components of vascular risk.
TREATMENT

Lifestyle Management
At minimum, NCEP ATP III (2001) guidelines call for heightened implementation of therapeutic lifestyle changes as first line treatment. Grundy (2001) suggested that lifestyle management could considerably change the percentage of mortality in a 10 year period. A discussion of lifestyle changes includes several factors. While lifestyle changes are difficult, they are key to a positive outcome (Bersot, 2000; Davidson, 2002) .
Smoking Cessation. Smoking reduces HDL, reduces
oxygen in the blood, constricts arteries, and damages blood vessels. For 35 year old smokers, cessation increases life expectancy 28 months for men and 34 months for women (Kong, 2000) .
Weight Management. Increased weight makes the heart work harder, increases the risk of hypertension, and increases glucose and lipids which equal an increased risk for atherosclerosis. Studies have shown a weight loss of 5% to 10% in obese individuals with Type II diabetes, hypertension, or dyslipidemia resulted in improved glycemic control, reduced blood pressure, and an improved lipid profile. For the 35 year old population, of which less than 30% are overweight, weight reduction to ideal levels would increase life expectancy 2000; Szapary, 2002) .
Exercise. An appropriate aerobic exercise program keeps the heart muscle in shape and more efficient. A 35 year old woman, who exercises and consumes 2,000 calories per week could be expected to increase life expectancy by 6.2 months (Kong, 2000) .
Alcohol. Limiting alcohol intake to less than 1 oz. daily is important. Increased amounts of alcohol increase blood pressure and triglyceride levels and are empty calories that contribute to obesity (Stefanick, 1998) .
Fat. It is important to reduce intake of total cholesterol to less than 200 milligrams per day and saturated fat to less than 7% of daily calories (NCEP, 2001; Szapary, 2002) .
Fiber. Increased viscous (soluble) fiber (10 to 25 grams per day) and plant stanols/sterols are options to enhance LDL lowering.
Stress reduction. Stress increases the amount of fatty acids and cholesterol in the blood and increases blood pressure and heart rate.
Complementary Therapies
In recent years, there has been an expanse of natural and herbal remedies on the market. Some products may be used with other prescription medications. Frequently, individuals use products or dietary supplements without the knowledge of their health care provider. It is important to know how these products and medications are different and how they may interact with prescription medications. While these products are popular, generally no clinical trials have been conducted on natural and herbal products, and scientific knowledge is still limited.
Over the counter vitamins and complementary medications are not subject to approval by the U.S. Food and Drug Administration. Manufacturers of these products cannot claim the products will prevent, treat, or diagnose any disease. Manufacturers are not required to prove the product is effective. Finally, the quality and purity of the product may not be consistent between brands. For these reasons, it remains difficult for health care providers to assist clients in their use of over the counter supplements. Controlled clinical trials using both placebo and control groups need to be completed to assess validity and usefulness of current popular supplements.
To date, some nonprescription products have proven useful as modifiers of hypercholesterolemia. Fish oil is used specifically to reduce triglyceride levels using various doses daily (Rader, 2000b; Szapary, 2001) . New data from randomized controlled trials have been reported in relation to beneficial effects of omega-3 fatty acids on individuals with cardiovascular disease. These positive effects are believed to be associated with cardiac function, including anti-arrhythmic effects, hemodynamics, and effects on arterial endothelial function (Kris-Etherton, 2002) . Although fish oil use is outside the realm of "cholesterol management," the ATP III panel recognizes that fish oil can be a therapeutic option in secondary prevention related to the strength of recent data. This newer data and recommendations are not noted in the ATP III because the strength of the clinical trial evidence was only moderate at the time of its publication in the spring DECEMBER 2003, VOL. 51, NO. 12 of 2001. When fish oil is taken for lowering triglycerides or as a therapeutic option, it can have some gastrointestinal effects at the start of therapy. However, the dose can be titrated up to approximately 9 grams a day. Fish oil is best taken with food. It can accentuate the action of anticoagulants (e.g., warfarin [Coumadin] ) and anti-platelet drugs, (e.g., aspirin, nonsteroidal antiinflammatory medication, ticlopidine [Ticlid], clopidogrel [Plavix]) (Harris, 1990) .
Plant stanols and sterols are food additives used to decrease the absorption of cholesterol their use has been reinforced by the NCEP ATP III guidelines (2001) . Plant stanol ester is a patented ingredient synonymous with the commercial product Benecol. Benecol is marketed as a margarine product that must be used with each meal to obtain optimal results. When used three times daily, a mean reduction of serum LDL cholesterol of approximately 15% can be achieved. This can be a costly choice, because it must be used with each meal. However, it does offer promise as an adjunct to standard medications in the future (Szapary, 2002) .
Pharmaceutical Interventions
In even the most motivated individuals, it may be difficult to reduce LDL cholesterol levels to a specific goal without the use of pharmaceutical modalities. Although LDL cholesterol remains the primary focus of intervention, other forms of therapy are important such as aspirin, folic acid, beta-blockers, and angiotensin converting enzyme inhibitors, depending on the primary or secondary status of the client. Risk and benefits for antioxidant vitamin use are in question at this time. Several trials have indicated that they are of no benefit in reducing vascular risk (Brown, 2001) . More research is necessary to clarify this matter. Pharmacological interventions for cholesterol include niacin, bile acid sequestrants, intestinal absorption inhibitors, HRT, fibrates, fish oil (omega-3 fatty acids), and 3-hydroxy-3-methyl glutaryl (HMG) co-reductase inhibitors or statins.
Niacin. Niacin is a B3 vitamin and was first used to lower cholesterol in 1955. Niacin affects cholesterol by decreasing total cholesterol and triglycerides. It also increases HDL and Jowers LDL. Some of the agents available are immediate release niacin, slow release niacin, and the prescription form of niacin, Niaspan, which is an intermediate release form (Brown, 2001; Castelli, 1984; Rader, 2002) .
Although the action mechanism of niacin is poorly understood, it is known to decrease VLDL. Niacin, which decreases LDL, has been suggested to shift the LDL particle density gradient to larger and more buoyant. It is the drug of choice for increasing HDL. Side effects such as flushing and itch can occur, and range from 15% at 1 gram to 26% at 2 grams. When niacin is taken with a low fat snack and caffeine, hot beverages, and spicy foods are avoided, this side effect can be averted. Niacin appears to have a complimentary effect when combined with other lipid lowering medications. There is less than a 4% increase in the risk of side effects, liver function tests changes, and myositis.
Niacin increases HDL; decreases LDL, Lp(a), total cholesterol, LDL molecular size, and triglycerides; and has been noted to decrease fibrinogen by influencing hepatic fibrinogen synthesis directly or secondarily via its hypolipidemic effects (Bersot, 2000) .
Bile Acid Sequestrants. Resins or bile acid sequestrants provide a nonabsorbable anionic exchange column. They bind bile, preventing enterohepatic reabsorption and increasing fecal excretion. The agents commonly used are cholestyramine (Questran), colestipol (Colestid), and colesevelam (Welchol). Bile acid sequestrants affect lipids by lowering LDL, but this class of medication can raise triglycerides, is neutral to or decreases HDL, has no effect on Lp(a), and is neutral or decreases LDL (Jacobson, 2000; Lipids Research Clinics Program, 1994; LIPID Study Group, 1998; NHANES III, 2000) .
Resins are rarely used as monotherapy. They are started at a low dose and are increased gradually. They are taken before or with a meal. It is necessary to increase fluid intake and dietary fiber to avoid constipation. This category combines well with other forms of lipid lowering medication. It is the drug of choice for individuals with liver disease and, when possible, with children (McKenny, 2001; Rader, 2000b) .
Intestinal Absorption Inhibitors. The newest class of anti-hypercholesterolemic medications is intestinal absorption inhibitors. To date, the only medication in this class is ezetimibe (Zetia), released in November 2002. It selectively inhibits the intestinal absorption of cholesterol and related phytosterols. ezetimibe localizes and appears to act at the brush border of the small intestine and inhibits cholesterol absorption (Gagne, 2002) . This inhibition results in a decrease in the delivery of intestinal cholesterol to the liver, a reduction of hepatic cholesterol stores, and an increase in clearance of cholesterol from the blood. This differs from statin therapy because ezetimibe reduces the delivery of cholesterol to the liver and statins reduce cholesterol synthesis in the liver.
As monotherapy for primary hypercholesterolemia, it is indicated as adjunctive therapy to diet for reducing elevated total cholesterol, LDL cholesterol, and apo B. Although indicated for use as monotherapy for moderate reduction of LDL cholesterol, the distinct mechanism of ezetimibe is complementary to statins. It has been evaluated for safety in combination studies in more than 2,000 clients (Gagne, 2002) . Adverse events were generally similar between ezetimibe plus statin and statin alone. Recommended dose is one I 0 mg tablet daily, and can be administered with or without food. It may be administered at the same time as a statin.
Fibrates. Fibrates are the drugs of choice for increased VLDL (Rader, 2000b; Szapary, 2001 ) . They are safely administered in combination with statins, as long as renal function is normal. Fenofibrate (Tricor) has been found to be more efficacious than the previous fibrate. Fenofibrate decreases triglycerides by 32% to 53% and increases HDL by 2% to 26%. In comparison, gemfibrozil decreased triglycerides by 31 % to 35% and increased HDL by 6% to 10%. The mechanism of action is decreased hepatic secretion of VLDL, decreased release of free fatty acids from adipose tissue, and peroxisome proliferutor activated receptor (PPAR) activation (especially with fenofibrate). Activation of PPAR includes a nuclear hormone receptor gene superfamily and the ability to function as a transcription activator or suppressor for genes involved in lipoprotein metabolism.
Gemfibrozil, both Lopid and the generic, has been used since 1982. Fenofibrate (Tricor) was introduced into the United States in 1998, although it has been used in Europe since 1975. These agents can increase or decrease LDL, decrease triglyceride, and increase HDL.
Omega-3 fatty acids. Omega-3 fatty acids are found in cold water fish. The mechanism of action is unknown, but the effect is a decrease in triglycerides. This is especially true when hypertriglyceridemia is secondary to increased chylomicrons. Side effects are palatability (fish taste and odor), gastrointestinal distress, and antiplatelet effects manifested by bruising and nosebleeds. The usual dose is 4 to 12 grams per day in divided doses with meals. With 4 grams per day, the response has been a 39% drop in triglycerides and a 6% increase in HDL. The effects with 9 to 12 grams per day have been a 60% to 80% drop in triglycerides. As previously stated, new findings suggest that fish oil at 2 grams daily is a reasonable addition to the treatment regimen for cardio protection in those with cardiac disease.
Stalins of HMG Co-reductase Inhibitors. Statins of
HMO co-reductase inhibitors were discovered in 1976. They are the drug of choice for reducing LDL cholesterol. Their mechanism of action is the reversible competitive inhibitors of HMO coenzyme-A reductase, which is the rate limiting step in the synthesis of cholesterol. Statins are also believed to be responsible for regulating LDL receptor activity in hepatocytes, allowing for LDL cholesterol to be brought back into the liver for increased cholesterol clearance (Downs, 1998; Herbert, 1997; Knopp, 1999; Roberts, 1996; Rubins, 1999; Sacks, 1996; Scandinavian Simvastatin Survival Study Group, 1994) . Current research theories support that, beyond lowering LDL, statins of HMO co-reductase inhibitors may have anti-inflammatory effects, affect plaque stabilization, decrease thrombus formation, and restore endothelial tissue.
The recent Heart Protection Study Collaborative Group (2002) reinforced this notion. In that study, more than 20,000 clients with known vascular disease hypertension, or diabetes and low to average LDL cholesterol were found to have a reduction in incidences of death, Ml, stroke, and revascularization with the implementation of simvastatin, regardless of total or LDL cholesterol levels at baseline, age, or gender.
Statin agents available include lovastatin (Mevacor, released in 1987 ), pravastatin (Pravachol, released in 1991 ), simvastatin (Zocor, released in 1991 ), fluvastatin (Lesco!, released in 1993 ), atorvastatin (Li pi tor, released in 1997 ), and rosuvastatin (Crestor, released in 2003 . Several trials have identified the safety and efficacy of statin therapy to reduce LDL and vascular events (Downs, 1998; LIPID Study Group, 1998; Rubins, 1999; Sacks, 1996; Scandinavian Simvastatin Survival Study, 1994; West of Scotland Coronary Prevention Group, 1998) .
Even with maximum doses of statins, triglycerides may still be too high, and HDL may still be too low. Perti-nent to the NCEP ATP III, after LDL is at target for that individual, triglycerides and HDL become secondary targets for intervention (NCEP, 2001) . Combination therapy is often required to meet these specific treatment targets. Independent risk factors also need to be considered, related to their effects on the profile. Their absence or presence represents adjuncts in choosing the class of anti-hyperlipemic medication that will be used in combination with traditional statin therapy. Selection of additional agents should always be considered in terms of their safety, effectiveness, and cost of care (Brown, 2001; Wolfe, 2001 ) .
Combination Lipid Lowering Medications. Use of current guidelines, along with independent risk factors, serve as a complete and thorough assessment for the development of an individual treatment plan for the client with a known or potential disease. Currently, there is one combination lipid lowering medication marketed under the name of Advicor (combination niacin and lovastatin). It consists of Mevacor and Niaspan therapy. Clinical trials have found this combination to be safe and efficacious. It is likely that more combination lipid lowering therapies will be developed because many clients require use of more than one class of medication to reach all the targets set in NCEP ATP III.
ROLE OF THE OCCUPATIONAL HEALTH NURSE
The first line of health care delivery for employed adults is often the occupational health nurse (Rogers, 2003) . Employees have built a relationship with the nursing staff and know they can be trusted. Although occupational health nurses work for the company, they are also perceived as champions of the workers. Many employees may not have primary care physicians, and will look to the occupational health nurse for health information. Nurses need to meet the challenge and broaden their knowledge base to be as effective as possible.
Part of the occupational health nursing role is client advocate. Through their professional relationships, the occupational health nurse and employee develop trust and credibility. Clients understand they will be treated with respect, listened to with concern, and given accurate information.
Early intervention can decrease catastrophic events and offer clients a better quality of life. Occupational health nurses are in a unique position because, for the most part, they see healthy clients, though some clients have chronic disease processes. Clients have lower acuity levels, but may require continuous monitoring of health conditions. Occupational health nurses know which employees are being treated for hypertension, diabetes, cardiovascular disease, and dyslipidemia. They provide support for employees to continue positive behaviors by helping track their progress.
Tracking forms encourage follow up, both by the occupational health nurse and the client's health care provider. When weight and blood pressure are monitored on the same form with lab results, progress is evident to all. This is useful in providing positive reinforcement and continued progress as the client and occupational health nurse partner in the health care plan. The record can be DECEMBER 2003, VOL. 51, NO. 12 copied with written permission of the employee and easily shared with other health care providers.
The standards of occupational health nursing practice delineate the care delivered. The assessment process begins with data collection, both subjective and objective. A baseline is prepared and the information collected is documented and retrievable. The occupational health nurse uses the information to formulate a nursing diagnosis and to plan interventions (Salazar, 2001) .
The outcome identification process enables the nurse to recommend action steps for employees. These steps are designed to lead to healthier lifestyle practices. The outcomes identified should be measurable so employees can chart their progress.
The occupational health nurse, the employee, and the employee's personal health care provider must work together to develop a care plan to achieve optimal results. Agreement must be reached on outcomes desired and target dates assigned for accomplishments. The occupational health nurse can assist the client with planning the strategies needed to achieve personal health goals. A written plan is essential. If goals are written, they are more likely to be achieved.
For the occupational health nurse to implement the interventions necessary for a successful outcome, clients need to be aware of current treatment modalities, prevention strategies, and health promotion programs. The evaluation process enables the occupational health nurse and client to examine the changes made, deciding what is working and what areas require more support.
The key to successful health promotion programs is to know the population. What are their health care issues? What information is needed and how will it be communicated? The occupational health nurse can access local hospital and community programs and local agencies of national organizations (e.g., American Heart Association), to obtain free information on a variety of topics. The Wellness Councils of America offers "train the trainer" programs with ideas and publications to help develop myriad programs. The occupational health nurse can build a library of brochures and lists of resources available. When an appointment is made to counsel an employee, the nurse has a ready supply of information to offer.
With a plan in place, the occupational health nurse meets with the employee. The appointment should be for a minimum of 20 minutes. This provides time to encourage the client to discuss concerns, fears, and successes, and for the occupational health nurse to determine the client's level of understanding. This is essential to support the individual. The occupational health nurse must know what clients understand about their medical conditions, as well as what is expected of them as they work toward a goal of a healthier lifestyle (Jairath, 1999) . Current lab values should be reviewed and recorded, along with weight, blood pressure, medications, nutrition, and exercise goals. At this first meeting, it is important to determine how often the nurse and client will meet to evaluate progress. A weekly meeting, even a brief one, is an effective way to keep the client on track and to offer encouragement for progress made.
SUMMARY
Vascular disease is basically an inherited metabolic disease. Eighty percent of individuals who develop disease have the same blood cholesterol levels as individuals who do not develop disease. With vascular disease pervasive throughout the world and current assessment techniques insufficient to identify those at risk, use of a multifactorial approach to vascular assessment is prudent. Assays are currently available that enable health care providers to determine risk beyond those traditionally used. These "novel" risk factors appear to be additive (Brown, 2001; Rader, 2000a Rader, , 2002 Superko, 1995) , and when combined with traditional factors, LDL can be adjusted to prevent disease. In individuals with established disease, these factors can be instrumental in identifying an appropriate treatment protocol for halting the progression of disease.
To date, the health care establishment as a whole has done a poor job of identifying and thoroughly treating cardiovascular risk. Even when risks were identified, often treatment protocols have not been aggressive enough to reach targeted goals (Hoerger, 1998; Jacobson, 2000; NHANES III, 2000) . The unique role of the occupational health nurse offers an opportunity to follow a client during long periods of time. This is useful in establishing trust and getting to know the specific problems of each individual. The occupational health nurse, therefore, stands at the threshold of change for the client, easing and assisting the client to reach individual goals. This group of nurses can play a significant role in forging prevention and stamping out the number one killer of the American population. AAOHN Journal 2003; 51(12), 521-531. Cardiovascular disease is responsible for more deaths each year than any other health problem in the United States. This has been true for more than 100 years.
IN SUMMARY
Identification and Management of
Traditional assessments have been unsuccessful in identifying individuals at high risk for developing cardiovascular disease.
Selected independent risk factors can be used to enhance nurses' assessment of clients who may be at high risk for developing cardiovascular disease.
Taking a proactive stance In assessment and Identification will be useful In stemming the tide of the cardiovascular epidemic In the United States.
